Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
Apply on Grants.gov →Application closes July 2, 2027
- Posted
- December 6, 2024
- Closes
- July 2, 2027
- Cost sharing
- No
- Instrument
- Grant
- Assistance listing
- 93.350
- Category
- Health
- Archives
- August 1, 2027
Program funding history
Awards made under Assistance Listing 93.350 across FY2025–FY2027, from public federal spending records.
- FY2025 obligated
- $599.3M
- FY2026 obligated
- $627.8M
- FY2027 (to date) obligated
- $0
- Awards in window
- 772
Top recipients: Vanderbilt University Medical Center, University of Pittsburgh - of the Commonwealth System of Higher Education, Regents of the University of Michigan, Trustees of the University of Pennsylvania, the, The Johns Hopkins University
Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →
Synopsis
This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for a variety of rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning.
Who can apply
- County governments
- Small businesses
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized tribal governments)
- Private institutions of higher education
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Public and State controlled institutions of higher education
- Special district governments
- Independent school districts
- City or township governments
- Public housing authorities/Indian housing authorities
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- For profit organizations other than small businesses
- State governments
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
How to apply
Applications go through the official government listing. Grants Radar links you straight to the source — applying is free.
View on Grants.gov Full announcement
New to federal funding? How to read an announcement · Who can apply · How grants work
Remind me before this closes
One email about a week before this grant closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.
Similar grants
- Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)
- Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25 - Clinical Trial Not Allowed)
- NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
Same-day alerts, matched to you
The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.
Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.
See pricing